B
18.90
-1.22 (-6.06%)
| Previous Close | 20.12 |
| Open | 20.02 |
| Volume | 2,630,653 |
| Avg. Volume (3M) | 605,280 |
| Market Cap | 677,660,160 |
| Price / Earnings (TTM) | 1.39 |
| Price / Sales | 118.71 |
| Price / Book | 2.94 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,133.43% |
| Diluted EPS (TTM) | -1.98 |
| Total Debt/Equity (MRQ) | 3.29% |
| Current Ratio (MRQ) | 13.68 |
| Operating Cash Flow (TTM) | -53.21 M |
| Levered Free Cash Flow (TTM) | -34.85 M |
| Return on Assets (TTM) | -19.54% |
| Return on Equity (TTM) | -30.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | BioAge Labs, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 0.75 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 66.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redpoint Management, Llc | 30 Sep 2025 | 383,254 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (Piper Sandler, 286.24%) | Buy |
| Median | 62.00 (228.04%) | |
| Low | 12.00 (Morgan Stanley, -36.51%) | Hold |
| Average | 49.00 (159.26%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 17.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 18 Feb 2026 | 62.00 (228.04%) | Buy | 19.59 |
| Piper Sandler | 27 Jan 2026 | 73.00 (286.24%) | Buy | 19.60 |
| Morgan Stanley | 08 Dec 2025 | 12.00 (-36.51%) | Hold | 11.83 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | BioAge Announces Pricing of Upsized $115.0 Million Public Offering |
| 20 Jan 2026 | Announcement | BioAge Announces Proposed Public Offering |
| 20 Jan 2026 | Announcement | BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 |
| 12 Jan 2026 | Announcement | BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk |
| 04 Dec 2025 | Announcement | BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor |
| 25 Nov 2025 | Announcement | BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |